Key Highlights

  • IQVIA data showed national Market Share gains for Activated Probiotics.
  • 230+ patients enrolled.
  • Five-year Huntsville agreement.
  • The three companies reported quarterly healthcare updates.

Three ASX healthcare companies filed quarterly updates. Biome Australia (ASX:BIO), EMVision (ASX:EMV) and Artrya (ASX:AYA) each published an update that is covered below.

Biome Australia (ASX:BIO): Sales

IQVIA figures for the 52 weeks to 3 October 2026 show share gains nationally and in each region, with Biome Daily leading probiotics in pharmacy by units and value. Wholesaler sales to pharmacy were a quarterly record.

Manufacturing with Specialty Probiotics Australia is under way, targeting Australian-made stock from November 2026. A heads of agreement with H&S Global gives exclusive cross-border E-commerce distribution in mainland China for three years, with exclusivity for year one and completion subject to a master distribution agreement. Larger Biome Daily 60 packs launch in Q2 FY27.

EMVision (ASX:EMV): Trial

Most patients count toward the 300 primary analysis target.

An acute ischaemic stroke detection feature will be validated within the trial, with FDA feedback sought in coming months.

Artrya (ASX:AYA): Huntsville

Its largest customer signed a five-year deal.

Northeast Georgia is expanding, Cone Health is nearing deployment, and Tanner Health's mid-September pre-authorisation workflow raised Salix Coronary Plaque use into October.

Why These Updates Could Matter

Biome Australia: Local production changes where products are made and the China agreement is still at heads-of-agreement stage. EMVision: Enrolment shows progress toward the primary analysis. Artrya: Study-to-customer conversion shows how evidence leads to sales.

The Takeaway

Biome Australia (ASX:BIO), EMVision (ASX:EMV) and Artrya (ASX:AYA) each issued quarterly healthcare updates, summarised above using the figures in their filings.